RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference
New York, NY – September 02, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at the H.C. Wainwright 22nd Annual Global Investment